Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
Biol Blood Marrow Transplant. 2014 Mar;20(3):295-308. doi: 10.1016/j.bbmt.2013.10.013. Epub 2013 Oct 17.
Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment for malignancies such as multiple myeloma (MM) and lymphomas. Various changes in the field over the past decade, including the frequent use of tandem aHSCT in MM, the advent of novel therapies for the treatment of MM and lymphoma, and the addition of new stem cell mobilization techniques, have led to the need to reassess current stem cell mobilization strategies. Mobilization failures with traditional strategies are common and result in delays in treatment and increased cost and resource utilization. Recently, plerixafor-containing strategies have been shown to significantly reduce mobilization failure rates, but the ideal method to maximize stem cell yields and minimize costs associated with collection has not yet been determined. A panel of experts convened to discuss the currently available data on autologous hematopoietic stem cell mobilization and transplantation and to devise guidelines to optimize mobilization strategies. Herein is a summary of their discussion and consensus.
自体造血干细胞移植（aHSCT）是治疗多发性骨髓瘤（MM）和淋巴瘤等恶性肿瘤的成熟方法。过去十年中，该领域发生了各种变化，包括 MM 中频繁使用串联 aHSCT、新型疗法治疗 MM 和淋巴瘤的出现以及新的干细胞动员技术的加入，这使得需要重新评估当前的干细胞动员策略。传统策略的动员失败很常见，导致治疗延迟、增加成本和资源利用。最近，含有培非格司亭的策略已被证明可显著降低动员失败率，但尚未确定最大限度地提高干细胞产量和降低与采集相关成本的理想方法。一组专家聚集在一起讨论目前关于自体造血干细胞动员和移植的可用数据，并制定优化动员策略的指南。以下是他们讨论和达成共识的摘要。
